GlassScriptPhysician profile
David S Yee
NPI 1639225675
$202,399.82
in general payments reported to CMS, 2019-2025
27 companies · $74K in 2025
The $74K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $18K · 2021: $4,609 · 2022: $33K · 2023: $30K · 2024: $12K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Travel and Lodging: $11K · Food and Beverage: $8,024 · Consulting Fee: $5,560 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,328.27 |
| Travel and Lodging | $10,657.56 |
| Food and Beverage | $8,023.57 |
| Consulting Fee | $5,559.50 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $124,451.78 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Pfizer INC. | $30,093.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15,537.71 | 2021-2025 | |
| Astellas Pharma US INC | $8,585.75 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $8,126.47 | 2023 | Orgovyx |
| C. R. Bard, INC. & Subsidiaries | $6,961.43 | 2023-2025 | Bard Urinary Drainage Bag, Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire, Totalis Flexible Endo Kit |
| Janssen Scientific Affairs, LLC | $2,778.47 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $2,487.31 | 2019-2025 | Lumenis Pulse 120h, Lithovue, Rezum Generator |
| Myovant Sciences INC. | $1,248.64 | 2021-2022 | |
| Cook Medical LLC | $314.30 | 2021-2024 | Fiber Dust, Litho 150 |
| Ferring Pharmaceuticals INC. | $278.51 | 2024-2025 | Adstiladrin |
| Astellas Pharma Global Development | $242.74 | 2021-2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $225.00 | 2022-2023 | Lynparza |
| Immunitybio, INC. | $206.63 | 2025 | |
| Urogen Pharma, INC. | $149.45 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photocure INC | $148.32 | 2021 | |
| Genzyme Corporation | $124.99 | 2019 | |
| Glaxosmithkline, LLC. | $121.37 | 2025 | Nucala |
| Karl Storz Endoscopy-America | $97.54 | 2020 | |
| Tolmar, INC. | $80.16 | 2023 | |
| Procept Biorobotics Corporation | $53.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $43.55 | 2025 | |
| Abbvie INC. | $18.36 | 2025 | |
| Stryker Corporation | $16.70 | 2024 | Fluid Management System |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.